Swedish respiratory health startup NuvoAir announced that Roche Italy will distribute its digital respiratory technology to certain cystic fibrosis (CF) centers across Italy.
According to Mayo Clinic: “Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body.” This condition causes a build-up of sticky mucus in the lungs and in the digestive system. There is no known cure for cystic fibrosis. Lung infections are treated with antibiotics which may be given intravenously, inhaled, or by mouth. Approximately 100,000 people are affected by Cystic fibrosis globally.
NuvoAir’s respiratory platform is designed to allow patients to assess lung function at home. Using this platform they can answer questionnaires regarding specific symptoms, track the progression of their condition, and share data with the caregivers in real-time.
“We are honored to partner with Roche,” NuvoAir founder & CEO Lorenzo Consoli said in a news release, reports MassDevice. “We are working with many CF centers across Europe, but never in partnership with a pharmaceutical company. Roche Italy is showing that it wants to position the customer at the center of its strategy and to think holistically about the customer experience. Thanks to Roche Italy, CF patients in Italy will now be able to benefit from a solution that helps them improve the management of their disease.”
“We are delighted to begin this partnership with NuvoAir,” added Roche Italy’s Elia Ganzi. “NuvoAir has designed an excellent respiratory platform that truly has the potential to deliver concrete medical advancements to CF patients during their disease path and optimize workflow for the medical team. This partnership is very strategic for us, with a view to promoting an open innovation path that makes Roche more and more a supplier of integrated healthcare solutions and not just drugs.”
Headquartered in Stockholm, Sweden, NuvoAir combines hardware, software and machine learning to improve lives of patients suffering from respiratory conditions and to enable better and faster clinical decisions.